Effect of short-term postoperative use of Rivaroxaban on radial artery stenosis and occlusion after percutaneous coronary intervention: The RESTORE Randomized Trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900026974

Enrollment

Unknown

Registered

2019-10-27

Start date

2020-05-30

Completion date

Unknown

Last updated

2021-12-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Artery disease

Interventions

Experimental:rivaroxaban 10mg qd

Control group:Placebo

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Patients undergoing diagnostic coronary angiography or percutaneous coronary intervention via the radial artery; 2. Allen's test was negative; 3. Ability to provide written informed consent.

Exclusion criteria

Exclusion criteria: 1. Failed of right radial artery puncture; 2. Current anticoagulation for other indication; 3. Contraindicated to anticoagulation or high bleeding risk(eg, gastrointestinal bleeding within 1 month; previous hemorrhagic stroke or ischemic stroke within 3 months; eGFR <30 ml/min/m2; severe liver dysfunction; platelet count <50 x 10^9/L); 4. Allergy to rivaroxaban; 5. Hemo-dynamic instability.

Design outcomes

Primary

Measure	Time frame
Right radial artery occlusion;	—

Secondary

Measure	Time frame
Lumen diameter of right radial artery;Flow velocity of the right radial artery;	—

Countries

China

Contacts

Public ContactShan Peiren

The First Affiliated Hospital of Wenzhou Medical University

prshan@126.com+86 13867709618

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 12, 2026